<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="80573">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01861847</url>
  </required_header>
  <id_info>
    <org_study_id>2905</org_study_id>
    <nct_id>NCT01861847</nct_id>
  </id_info>
  <brief_title>7-Keto DHEA for the Treatment of PTSD</brief_title>
  <official_title>7-Keto DHEA for the Treatment of PTSD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bay Pines VA Healthcare System</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Humanetics Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bay Pines VA Healthcare System</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Data and Safety Monitoring Board</authority>
    <authority>United States: Federal Government</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to test the effectiveness of 7-Keto DHEA in reducing
      symptoms of Post-Traumatic Stress Disorder (PTSD).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2013</start_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Psychological benefits of 7-Keto DHEA (Dehydroepiandrosterone) in Veterans suffering from PTSD participating in the intervention through questionnaires and corresponding measurement of blood work for amounts of DHEA.</measure>
    <time_frame>Four months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Outcome measures include analysis in symptoms of depression, anxiety, stress, trauma, and improved memory and cognitive functioning after treatment with 7-Keto DHEA.  Measures will include psychological questionnaires as follows:
PCL-C (PTSD Checklist) ASP (Associated Symptoms of PTSD Scale) TSI (Trauma Symptom Inventory) DES (Dissociative Experience Scale) BDI-II (Beck Depression Inventory - II) BSI (Brief Symptom Inventory) QOLI (Quality of Life Inventory)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Physiological benefits of 7-Keto DHEA (Dehydroepiandrosterone) in Veterans suffering from PTSD participating in the intervention through questionnaires and corresponding measurement of blood work for amounts of DHEA.</measure>
    <time_frame>Four months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>DHEA (DHEA-S) concentrations (serum, saliva) are often elevated in men and women suffering from PTSD including that related to combat experience. Several studies have shown an association between higher levels of DHEA/DHEA-S and abatement of PTSD symptoms.  Outcome measures include analysis  of medical assessments via blood work; CBC (Complete Blood Count), Cortisol, and DHEA sulfate level</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>PTSD</condition>
  <arm_group>
    <arm_group_label>Placebo Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>7 Keto-DHEA</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>7-Keto Dehydroepiandrosterone</intervention_name>
    <arm_group_label>Drug group</arm_group_label>
    <other_name>7-Keto DHEA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Veteran status and enrolled for care in the Veteran Health Administration

          -  Ages 18-64

          -  Primary diagnosis of PTSD as assess by the clinician administered PTSD scale and
             independent clinical mental health evaluation

        Exclusion Criteria:

          -  psychosis

          -  Dementia

          -  Active alcohol and/or substance abuse or dependence

          -  Active suicidal or homicidal ideation

          -  Medical concerns that would exclude use of 7-Keto DHEA
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Carol O'Brien, Ph.D.</last_name>
    <phone>727-398-6661</phone>
    <phone_ext>7579</phone_ext>
    <email>carol.obrien1@va.gov</email>
  </overall_contact>
  <location>
    <facility>
      <name>Bay Pines VA Healthcare System</name>
      <address>
        <city>Bay Pines</city>
        <state>Florida</state>
        <zip>33744</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carol O'Brien, Ph.D.</last_name>
      <phone>727-398-6661</phone>
      <phone_ext>7579</phone_ext>
      <email>carol.obrien1@va.gov</email>
    </contact>
    <investigator>
      <last_name>Carol O'Brien, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>May 23, 2013</lastchanged_date>
  <firstreceived_date>May 10, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Bay Pines VA Healthcare System</investigator_affiliation>
    <investigator_full_name>Carol O'Brien</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dehydroepiandrosterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
